Torres-Reyes Luis A, Alvarado-Ruiz Liliana, Piña-Sánchez Patricia, Martínez-Silva María G, Ramos-Solano Moisés, Olimón-Andalón Vicente, Ortiz-Lazareno Pablo C, Hernández-Flores Georgina, Bravo-Cuellar Alejandro, Aguilar-Lemarroy Adriana, Jave-Suarez Luis F
División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS) Guadalajara, Jalisco, Mexico ; Programa de Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud (CUCS)-Universidad de Guadalajara Guadalajara, Jalisco, Mexico.
Laboratorio de Oncología Genómica, Unidad de Investigación Médica en Enfermedades Oncológicas, Centro Médico Nacional Siglo XXI-IMSS Mexico.
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7409-18. eCollection 2014.
The transcription factor grainyhead-like 2 (GRHL2) is evolutionarily conserved in many different species, and is involved in morphogenesis, epithelial differentiation, and the control of the epithelial-mesenchymal transition. It has also recently been implicated in carcinogenesis, but its role in this remains controversial. Expression of GRHL2 has not previously been reported in cervical cancer, so the present study aimed to characterize GRHL2 expression in cervical cancer-derived cell lines (CCCLs) and cervical tissues with different grades of lesions. Microarray analysis found that the expression of 58 genes was down-regulated in CCCLs compared to HaCaT cells (non-tumorigenic human epithelial cell line). The expression of eight of these genes was validated by quantitative real-time PCR (qPCR), and GRHL2 was found to be the most down-regulated. Western blot assays corroborated that GRHL2 protein levels were strongly down-regulated in CCCLs. Cervical cells from women without cervical lesions were shown to express GRHL2, while immunohistochemistry found that positivity to GRHL2 decreased in cervical cancer tissues. In conclusion, a loss or strong reduction in GRHL2 expression appears to be a characteristic of cervical cancer, suggesting that GRHL2 down-regulation is a necessary step during cervical carcinogenesis. However, further studies are needed to delineate the role of GRHL2 in cervical cancer and during malignant progression.
转录因子颗粒头样蛋白2(GRHL2)在许多不同物种中具有进化保守性,参与形态发生、上皮分化以及上皮-间质转化的调控。最近它也被认为与癌症发生有关,但其在这方面的作用仍存在争议。此前尚未有关于GRHL2在宫颈癌中表达的报道,因此本研究旨在描述GRHL2在宫颈癌衍生细胞系(CCCLs)和不同病变分级的宫颈组织中的表达特征。微阵列分析发现,与HaCaT细胞(非致瘤性人上皮细胞系)相比,CCCLs中有58个基因的表达下调。其中8个基因的表达通过定量实时PCR(qPCR)得到验证,发现GRHL2是下调最明显的。蛋白质印迹分析证实CCCLs中GRHL2蛋白水平强烈下调。未患宫颈病变女性的宫颈细胞显示表达GRHL2,而免疫组织化学发现宫颈癌组织中GRHL2阳性率降低。总之,GRHL2表达缺失或显著降低似乎是宫颈癌的一个特征,提示GRHL2下调是宫颈癌发生过程中的一个必要步骤。然而,需要进一步研究来阐明GRHL2在宫颈癌及恶性进展过程中的作用。